Phase II data kill off Merck's vicriviroc
This article was originally published in Scrip
Executive Summary
Merck has confirmed that it is discontinuing the development of its CCR5 receptor antagonist HIV therapy vicriviroc. While the announcement was made with little fanfare and no media attention in July, the Phase II data supporting the decision was presented for the first time as a poster at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Boston on 13 September.